Valuation: Affimed N.V.

Market Cap 18.84M 21.13M 17.56M 15.97M 30.05M 2.05B 30.36M 211M 82.45M 1.04B 79.28M 77.59M 3.34B P/E 2022
-1.92x
P/E 2023 -0.8x
Enterprise Value -336K -377K -313K -285K -536K -36.51M -542K -3.76M -1.47M -18.58M -1.42M -1.38M -59.54M EV / Sales 2022
0.03x
EV / Sales 2023 4.69x
Free-Float
92.89%
Yield 2022 *
-
Yield 2023 -
1 week+200.00%
Current month+200.00%
1 month+200.00%
3 months+200.00%
Current year+200.00%
1 week 0
Extreme 0.0002
0
1 month 0
Extreme 0.0001
0
Current year 0
Extreme 1.0E-6
0.04
1 year 0
Extreme 1.0E-6
0.05
3 years 0
Extreme 1.0E-6
8.95
5 years 0
Extreme 1.0E-6
73.5
10 years 0
Extreme 1.0E-6
117.4
Manager TitleAgeSince
Chief Executive Officer 42 2024-09-02
Director of Finance/CFO 61 2023-12-30
Chief Executive Officer 65 2024-01-14
Director TitleAgeSince
Chairman 75 2006-12-31
Director/Board Member 71 2016-01-20
Director/Board Member 60 2020-08-03
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+200.00%+200.00%-99.99% 4.92K
-3.19%-3.19%+44.60%+87.98% 74.68B
-15.86%-16.67%+3.92%+50.90% 58.7B
-2.39%-2.05%+4.29%+31.33% 48.36B
-6.35%-8.35%+303.95%+651.28% 43.05B
+0.30%-3.71%+28.89%+30.33% 42.48B
-3.82%-4.32%+2.49%+101.36% 41.39B
-2.13%+1.07%+7.51%+50.31% 31.29B
-3.35%-6.35%-13.20%-17.22% 23.93B
-1.24%-11.97%-38.10%+311.13% 22.22B
Average -3.80%-2.37%+54.44%+119.74% 38.61B
Weighted average by Cap. -4.86%-1.88%+44.70%+136.42%

Financials

2022 2023
Net sales 42.87M 48.07M 39.96M 36.33M 68.37M 4.65B 69.07M 479M 188M 2.37B 180M 177M 7.59B 13.91M 15.6M 12.97M 11.79M 22.19M 1.51B 22.42M 156M 60.88M 769M 58.55M 57.3M 2.46B
Net income -86M -96.44M -80.17M -72.88M -137M -9.34B -139M -961M -376M -4.75B -362M -354M -15.23B -106M -119M -98.75M -89.78M -169M -11.5B -171M -1.18B -464M -5.85B -446M -436M -18.75B
Net Debt -172M -193M -160M -146M -274M -18.68B -277M -1.92B -753M -9.51B -724M -709M -30.47B -19.18M -21.51M -17.88M -16.25M -30.59M -2.08B -30.9M -214M -83.92M -1.06B -80.7M -78.97M -3.4B
Projected Income Statement - Annual - Affimed N.V.
Logo Affimed N.V.
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Employees
76
Date Price Change Volume
26-10-08 US$0.000300 0.00% 800
26-10-06 US$0.000300 +50.00% 1,155
26-10-05 US$0.000200 0.00% 293,770
26-10-02 US$0.000200 +100.00% 55,470
26-10-01 US$0.000100 0.00% 744

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Affimed N.V.
  1. Stock Market
  2. Stocks
  3. AFMDQ Stock